EPS for SteadyMed Ltd. (STDY) Expected At $-0.19

July 14, 2018 - By Carolyn Hewitt

SteadyMed Ltd. (NASDAQ:STDY) Logo

Analysts expect SteadyMed Ltd. (NASDAQ:STDY) to report $-0.19 EPS on August, 10.They anticipate $0.14 EPS change or 42.42 % from last quarter’s $-0.33 EPS. After having $-0.39 EPS previously, SteadyMed Ltd.’s analysts see -51.28 % EPS growth. The stock decreased 1.08% or $0.05 during the last trading session, reaching $4.6. About 12,400 shares traded. SteadyMed Ltd. (NASDAQ:STDY) has declined 34.29% since July 14, 2017 and is downtrending. It has underperformed by 46.86% the S&P500.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Coverage

Among 2 analysts covering Steadymed (NASDAQ:STDY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Steadymed had 2 analyst reports since April 9, 2018 according to SRatingsIntel. The company was downgraded on Tuesday, May 1 by JMP Securities. H.C. Wainwright maintained the shares of STDY in report on Monday, April 9 with “Buy” rating.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company has market cap of $122.48 million. The company's product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology. It currently has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

Another recent and important SteadyMed Ltd. (NASDAQ:STDY) news was published by Seekingalpha.com which published an article titled: “Merger Arbitrage Mondays – July 9, 2018” on July 09, 2018.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.